Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PG-033 by Single Dose Administration and Food Effect in Healthy Volunteers

NCT07013097 is registered in ClinicalTrials.gov with Prime Gene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07013097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07013097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PG-033 by Single Dose Administration and Food Effect in Healthy Volunteers
Lead sponsor
Prime Gene Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 23, 2025
Completion date
December 31, 2026
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lichen simplex chronicus